Age-related macular degeneration (AMD) once meant a slow, irreversible loss of vision, and many people still believe that's true. But the AMD of today isn't the AMD of ...
Treatment of Exudative (Wet) Age-Related Macular Degeneration (AMD): The Knowns and the Unknowns Sunir Garg, MD, considers what he has learned in the years since the first anti-VEGF therapies became ...
"Identifying an association between AMD and valvular heart disease may provide important insights to the pathogenesis of AMD, may serve as a biomarker for these diseases, and may potentially assist in ...
PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...
MIAMI, FLORIDA / ACCESS Newswire / February 18, 2025 / Telomir Pharmaceuticals, Inc. (TELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent ...
Age-related macular degeneration (AMD) is the nation's leading cause of blindness in older adults, outpacing even glaucoma and cataracts, and nearly 1% of Americans age 40 and older have ...
EURETINA 2024 In Gene Therapy for RP, LCA, the Earlier, the Better A real-world study of an FDA-approved gene therapy for inherited retinal disease shows younger patients gain more visual improvements ...
Hosted on MSN
Could AI Transform AMD Care? Experts Say Yes
Artificial intelligence (AI) is on the cusp of transforming how age-related macular degeneration (AMD) is diagnosed, monitored, and treated both in the medical office and at home, specialists say.
Hosted on MSN
Which Eye Specialist Treats Wet AMD?
Optometrists (healthcare providers who offer standard eye care) can diagnose wet age-related macular degeneration (AMD) but can't treat it. Therapies for wet AMD are primarily led by ophthalmologists ...
Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD ...
– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...
Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results